Appropriate and inappropriate use of oral glucocorticoid therapy in rheumatoid arthritis

Joint Bone Spine

Volumn 73, Issue 3, 2006, Pages 234-235

  Maillefert, Jean Francis ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Glucocorticoid therapy; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

DOSE RESPONSE; EDITORIAL; HUMAN; ORAL DRUG ADMINISTRATION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TIME;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; RISK ASSESSMENT; TIME FACTORS;

EID: 33646057691     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.11.006     Document Type: Editorial

References (10)

1. O'Dell J.R. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis Rheum. 46 (2002) 283-285
2. Boers M., Verhoeven A.C., Markusse H.M., van de Laar M.A.F.J., Westhovens R., van Denderen J.C., et al. Randomised comparison of step-down prednisolone, methotrexate and sulfasalazine with sulfasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
3. Landewé R.B.M., Boers M., Verhoeven A.C., Westhovens R., van de Laar M.A.F.J., Markusse H.M., et al. COBRA combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention. Arthritis Rheum. 46 (2002) 347-356
4. Maillefert J.F., Combe B., Goupille P., Cantagrel A., and Dougados M. Long-term structural effects of combination therapy in patients with early rheumatoid arthritis. Five-year follow-up of a prospective double blind controlled study. Ann. Rheum. Dis. 62 (2003) 764-766
5. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., van Zeben D., Kerstens P.J.S.M., Hazes J.M.W., Zwinderman A.E., et al. Clinical and radiological efficacy of different treatment strategies: 2 year follow-up of the BEST study. Ann. Rheum. Dis. 64 Suppl III (2005) 58 (Abs)
6. Lard L.R., Boers M., Verhoeven A., Vos K., Visser H., Hazes J.M., et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum. 48 (2003) 899-905
7. Van der Bijl A.E., Goekoop-Ruiterman Y.P.M., Breedveld F., Hazes J.M., Kerstens P.J., de Vries-Bouwstra J.K., et al. Many early rheumatoid arthritis patients with a good clinical response to infliximab can discontinue anti-TNF-alpha therapy without relapse. Ann. Rheum. Dis. 64 Suppl III (2005) 59 (Abs)
8. Combe B, Landewé R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis. Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 2006; (in press).
9. Maillefert J.F., and Saraux A. Efficacité et tolérance des corticoïdes utilisés en tant que "traitement de fond" dans la polyarthrite rhumatoïde. Rev. Rhum. 69 Suppl 2 (2002) 65s-71s
10. Moreland L.W., and O'Dell J.R. Glucocorticoids and rheumatoid arthritis. Back to the future?. Arthritis Rheum. 46 (2002) 2553-2563